This study is testing Sutetinib Maleate Capsule, a new oral medication, for people with locally advanced or metastatic non-small cell lung cancer (NSCLC). This drug works by targeting specific changes in the EGFR gene, which can cause cancer to grow. You may be able to join if you have NSCLC with certain uncommon EGFR mutations (L861Q, G719X, and/or S768I) and have had one or fewer prior chemotherapy treatments. Researchers want to see how many people respond to Sutetinib Maleate Capsule over two years. The study aims to enroll 99 participants, but its current status is unclear.

Study design

This is a Phase 2b, open-label study, meaning both you and your doctors will know you are receiving Sutetinib Maleate Capsule. It plans to include about 99 participants.

What's involved

You would take Sutetinib Maleate Capsule by mouth, with or without food (food is preferred), for up to 13 cycles.

Compensation

Not stated in the trial record.

Follow-up

Researchers will assess your response to the treatment for up to two years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.